ReShape Lifesciences Inc. (RSLS)

NASDAQ: RSLS · IEX Real-Time Price · USD
0.154
-0.005 (-3.39%)
At close: Feb 23, 2024, 4:00 PM
0.151
-0.003 (-2.14%)
After-hours: Feb 23, 2024, 7:58 PM EST
-3.39%
Market Cap 3.61M
Revenue (ttm) 9.81M
Net Income (ttm) -26.30M
Shares Out 23.46M
EPS (ttm) -39.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 467,037
Open 0.160
Previous Close 0.159
Day's Range 0.150 - 0.160
52-Week Range 0.141 - 4.580
Beta 1.25
Analysts n/a
Price Target n/a
Earnings Date Mar 27, 2024

About RSLS

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCar... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Nov 15, 2007
Employees 40
Stock Exchange NASDAQ
Ticker Symbol RSLS
Full Company Profile

Financial Performance

In 2022, RSLS's revenue was $11.24 million, a decrease of -17.35% compared to the previous year's $13.60 million. Losses were -$46.21 million, -26.81% less than in 2021.

Financial Statements

News

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifescie...

3 days ago - GlobeNewsWire

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons

4 weeks ago - GlobeNewsWire

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has en...

2 months ago - GlobeNewsWire

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Improve the Patient Experience Company Initiating U.S. Product Launch IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ®  (Nasdaq: RSLS), the premier ...

2 months ago - GlobeNewsWire

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has e...

3 months ago - GlobeNewsWire

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023

3 months ago - GlobeNewsWire

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering

IRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of it...

5 months ago - GlobeNewsWire

ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI

IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. ...

5 months ago - GlobeNewsWire

ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System

Royalty-Bearing License Agreement Covers the Countries in the Indian Subcontinent, Representing Approximately 20% to 25% of the World's Population Royalty-Bearing License Agreement Covers the Countrie...

5 months ago - GlobeNewsWire

ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System

Granted One Patent from USPTO and Receives Two Notices of Allowance, Providing Foundational Protection Granted One Patent from USPTO and Receives Two Notices of Allowance, Providing Foundational Prote...

5 months ago - GlobeNewsWire

ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

$331,541 Grant will Explore the use of High-Resolution Endoscopic Ultrasound to Aid in the Placement of the DBSN™ Device $331,541 Grant will Explore the use of High-Resolution Endoscopic Ultrasound to...

5 months ago - GlobeNewsWire

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update

Company Executing Its Plan for Growth; Achieves Continued Improvement in Operational Effectiveness Reducing Second Quarter Operating Expenses by 53% Compared to Second Quarter of 2022

7 months ago - GlobeNewsWire

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update

IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will r...

7 months ago - GlobeNewsWire

ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software

Hive's AI- and SMS-based Patient-Self-Service Technology to Manage Prospective Lap-Band® Leads From Initial Contact Through Surgical Consultation Hive's AI- and SMS-based Patient-Self-Service Technolo...

8 months ago - GlobeNewsWire

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting

IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its pr...

8 months ago - GlobeNewsWire

ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Enhanced Band Reservoir Technology Designed to Improve the Patient Experience Enhanced Band Reservoir Technology Designed to Improve the Patient Experience

8 months ago - GlobeNewsWire

ReShape Lifesciences® to Participate in Investor and Industry Conferences in June

SAN CLEMENTE, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced particip...

9 months ago - GlobeNewsWire

ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update

Achieved Continued Improvement in Operational Effectiveness With First Quarter 2023 Operating Expenses Down 42.9% Compared to the First Quarter of 2022

10 months ago - GlobeNewsWire

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update

SAN CLEMENTE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it w...

10 months ago - GlobeNewsWire

ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes

SAN CLEMENTE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will pr...

10 months ago - GlobeNewsWire

ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of ...

10 months ago - GlobeNewsWire

ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market

SAN CLEMENTE, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it...

11 months ago - GlobeNewsWire

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System

SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the c...

11 months ago - GlobeNewsWire

ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call

SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it...

11 months ago - GlobeNewsWire

ReShape Lifesciences Announces Formation of International Scientific Advisory Board

Top Industry Experts in Bariatric Surgery and Obesity Will Help Solidify ReShape's Position as the Premier Physician-Led Weight Loss and Metabolic Health Solutions Company Top Industry Experts in Bari...

1 year ago - GlobeNewsWire